Contact Us
Current Deals

Company Details

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

  • www.afdil.com/
  • Sector: Healthcare
  • CHRYSEUM SCORE: 5.00/10.00
    ×

    ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

    • Sector: Healthcare
    • CHRYSEUM SCORE: 5.00/10.00

    Description: Anglo-French Drugs and Industries has market leading brands in nutraceuticals, CNS, skin and respiratory segments.

    Evaluation is basis the latest financial year disclosures filed by the company

    Valuation

    Max Score: 3.50

    P/E of Company

    16.40

    AVG P/E of Key Peer/s

    20.02

    Valuation Score

    2.50

    The Valuation Score depicts if the company is available at a discount when compared to its listed/unlisted peers. Higher the discount, more is the score given to the company.

    Growth

    Max Score: 3.50

    Sales Growth

    -18.94%

    PAT Growth

    70.76%

    ROE

    5.79%

    Growth Score

    1.00

    The Growth Score accounts for the growth in Sales and PAT on a 3 year CAGR basis and the Company’s ROE as per the latest financial year results released by the company.

    Leverage

    Max Score: 1.50

    Debt / Equity

    0.15

    AVG Industry Debt / Equity

    0.01

    Leverage Score

    0.00

    Lower the Debt/Equity, higher the score.

    Management Quality

    Max Score: 1.50

    Board Structure & Composition

    1.00

    Related Party Transactions

    1.00

    Timely Disclosure

    1.00

    Management Score

    1.50

    This score represents a consolidated view of the Company’s Management Quality, which includes Board Structure, Related Party Transactions and Timely disclosures. Each parameter is scored out of 1.

₹1540.00 0.00 (0.00%)

As on 05 Jun, 2026
L 960.00 52 Week Range H 3030.00
Company Description : Anglo-French Drugs and Industries has market leading brands in nutraceuticals, CNS, skin and respiratory segments.
Company Overview
  • Name of Company ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED
  • Sector Healthcare
  • ISIN INE570E01016
  • Scrip Code ANGLO FRENCH
  • CIN L24230KA1923PLC010205
  • Pan No AAACA9756E
  • Face Value 10
  • Price ₹ 1540.00
  • No. of Shares outstanding 0.12 Cr.
  • Market Cap ₹ 189.94 Cr
Financials
  • Revenue from operations ₹ 87.79 Cr.
  • EBITDA ₹ 12.98 Cr.
  • EBITDA Margin % 14.79%
  • Profit After Tax ₹ 7.22 Cr.
  • PAT Margin % 6.12%
  • EPS 58.54
  • Stock P/E 26.31
  • Book Value Per Share 1,011.85
  • P/B 1.52
  • Debt/Equity 0.15
Other Key Statistics
  • 52 week High/Low 3030.00/960.00
  • Dividend Per Share 1.50
  • Dividend Yield 0.10%
  • Sales Growth - 3 years -18.94%
  • EBITDA Growth - 3 years 13.07%
  • PAT Growth - 3 years 70.76%
  • EPS Growth - 3 years 73.39%
  • ROE 5.79%
  • ROCE 7.14%
  • Cash Equivalents 1.17
All figures below are in INR Crores unless otherwise stated

Peer Comparison

Key Financials - FY25
Company Name Anglo-French Drugs and Industries Ltd Marksans Pharma Ltd
Listing Status Unlisted Listed
Revenue from Operations 87.79 2,622.84
Total Income 117.99 2,693.22
Finance Cost 1.85 11.66
Depreciation & Amortization 3.27 83.38
Total Expenses 110.13 2,189.25
EBITDA 12.98 599.01
PAT 7.22 382.61
No. of Shares Outstanding 0.12 45.32
EPS (in ₹) 58.54 8.40
Share Capital 1.23 45.31
Total Net Worth 124.80 2,489.38
Total Assets 192.40 3,239.63
Total Debt 19.01 23.08
Key Metrics:
CMP* 1,540.00 236.06
Market Cap (In Cr.) 189.94 10,698.24
Market Cap/Sales 1.61 3.97
EPS (Earnings Per Share) 58.54 8.40
BVPS (Book Value Per Share) 1,011.85 54.93
P/E 26.31 28.10
P/BV 1.52 4.30
EBITDA Margin 14.79% 22.84%
ROE 5.79% 15.37%
ROA 3.75% 11.81%
*Market Price in ₹ as on 05 Jun, 2026

Profit Loss

FY25 FY24 FY23 FY22 FY21
Revenue from operations 87.79 95.20 102.51 164.80 153.78
Y-o-Y Revenue Growth -7.78% -7.13% -37.80% 7.17% 18.13%
Other Income 30.20 4.64 7.59 0.81 1.02
Total Income 117.99 99.84 110.10 165.61 154.80
Total Expenses (Excludes Interest and Depreciation) 105.01 107.13 143.88 156.63 137.42
Operating Profit (After deducting Depreciation) -20.49 -15.08 -44.71 5.27 13.90
OPM % -23.34 -15.84 -43.62 3.20 9.04
EBITDA 12.98 -7.29 -33.78 8.98 17.38
Depreciation 3.27 3.15 3.34 2.90 2.46
EBIT 9.71 -10.44 -37.12 6.08 14.92
Interest 1.85 1.85 3.07 4.27 5.29
EBT before Exceptional Items 7.86 -12.29 -40.19 1.81 9.63
Prior period/Exceptional /Extra Ordinary Items 0.00 0.00 291.27 0.00 0.00
Profit before tax/EBT 7.86 -12.29 251.08 1.81 9.63
Tax 0.64 0.05 60.14 0.36 2.12
Net Profit 7.22 -12.34 190.94 1.45 7.51
Profit (loss) of minority interest 0.00 0.00 0.00 0.00 0.00
Total profit (loss) for period 7.22 -12.34 190.94 1.45 7.51
EPS in Rs 58.54 -100.05 1,478.44 11.23 58.22
EPS Change % -158.51% -106.77% 13,065.09% -80.71% 117.89%
EBITDA Change % -278.05% -78.42% -476.17% -48.33% 24.77%
Profit growth -158.51% -106.46% 13,068.28% -80.69% 141.48%
ROCE 7.14% -5.68% -15.81% 12.60% 40.23%
ROE 5.79% -7.22% 91.43% 7.86% 46.73%
Debt / Equity Ratio 0.15 0.05 0.12 1.88 2.47
Sales growth 3Years -18.94% -14.77%
Sales growth 5Years -7.58%
Dividend per share 1.50 1.50 20.00 1.50

Balance Sheet

FY25 FY24 FY23 FY22 FY21
Share Capital 1.13 1.23 1.29 1.29 1.29
Reserves 123.67 169.67 207.55 17.15 14.78
Total shareholders' funds 124.80 170.90 208.84 18.44 16.07
Borrowings 19.01 8.82 26.06 34.68 39.71
Other Liabilities 15.58 15.10 16.82 19.68 16.05
Total Liabilities 67.60 48.70 64.01 77.20 78.70
Fixed Assets 26.28 17.57 17.94 18.73 13.58
Capital WIP 0.00 0.00 0.00 0.00 0.00
Investments 0.48 125.20 166.99 0.20 0.08
Other Assets 115.44 20.40 10.41 8.28 6.93
Total Assets 192.40 219.60 272.85 95.65 94.77
Cash Equivalents 1.17 2.49 9.14 1.85 1.22
Total Current liability 56.35 35.67 38.07 47.40 57.68
Total Assets -Total Current liabilty 136.05 183.93 234.78 48.25 37.09

Cash Flow

FY25 FY24 FY23 FY22 FY21
Net Cash from / (used in) Operating Activity -16.05 -0.04 184.69 11.71 4.51
Net Cash from / (used in) Investing Activity 44.71 41.36 -170.40 -9.05 -0.79
Net Cash from / (used in) Financing Activity -46.00 -44.06 -11.70 -2.87 -3.31
Net Inc/Dec In Cash And Cash Equivalents 0.13 -2.74 2.59 -0.21 0.41

Share Holding Pattern

No. of Shares in Crs. % Holding
Promoters 0.08 65.24%
Non Promoters 0.04 34.76%

News

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

  • www.afdil.com/
  • Sector: Healthcare
  • CHRYSEUM SCORE: 5.00/10.00
    ×

    ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

    • Sector: Healthcare
    • CHRYSEUM SCORE: 5.00/10.00

    Description: Anglo-French Drugs and Industries has market leading brands in nutraceuticals, CNS, skin and respiratory segments.

    Evaluation is basis the latest financial year disclosures filed by the company

    Valuation

    Max Score: 3.50

    P/E of Company

    16.40

    AVG P/E of Key Peer/s

    20.02

    Valuation Score

    2.50

    The Valuation Score depicts if the company is available at a discount when compared to its listed/unlisted peers. Higher the discount, more is the score given to the company.

    Growth

    Max Score: 3.50

    Sales Growth

    -18.94%

    PAT Growth

    70.76%

    ROE

    5.79%

    Growth Score

    1.00

    The Growth Score accounts for the growth in Sales and PAT on a 3 year CAGR basis and the Company’s ROE as per the latest financial year results released by the company.

    Leverage

    Max Score: 1.50

    Debt / Equity

    0.15

    AVG Industry Debt / Equity

    0.01

    Leverage Score

    0.00

    Lower the Debt/Equity, higher the score.

    Management Quality

    Max Score: 1.50

    Board Structure & Composition

    1.00

    Related Party Transactions

    1.00

    Timely Disclosure

    1.00

    Management Score

    1.50

    This score represents a consolidated view of the Company’s Management Quality, which includes Board Structure, Related Party Transactions and Timely disclosures. Each parameter is scored out of 1.

₹1540.00 0.00 (0.00%)

As on 05 Jun, 2026
L 960.00 52 Week Range H 3030.00
Company Description : Anglo-French Drugs and Industries has market leading brands in nutraceuticals, CNS, skin and respiratory segments.
Company Overview
  • Name of Company ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED
  • Sector Healthcare
  • ISIN INE570E01016
  • Scrip Code ANGLO FRENCH
  • CIN L24230KA1923PLC010205
  • Pan No AAACA9756E
  • Face Value 10
  • Price ₹ 1540.00
  • No. of Shares outstanding 0.12 Cr.
  • Market Cap ₹ 189.94 Cr
Financials
  • Revenue from operations ₹ 87.79 Cr.
  • EBITDA ₹ 12.98 Cr.
  • EBITDA Margin % 14.79%
  • Profit After Tax ₹ 7.22 Cr.
  • PAT Margin % 6.12%
  • EPS 58.54
  • Stock P/E 26.31
  • Book Value Per Share 1,011.85
  • P/B 1.52
  • Debt/Equity 0.15
Other Key Statistics
  • 52 week High/Low 3030.00/960.00
  • Dividend Per Share 1.50
  • Dividend Yield 0.10%
  • Sales Growth - 3 years -18.94%
  • EBITDA Growth - 3 years 13.07%
  • PAT Growth - 3 years 70.76%
  • EPS Growth - 3 years 73.39%
  • ROE 5.79%
  • ROCE 7.14%
  • Cash Equivalents 1.17
All figures below are in INR Crores unless otherwise stated

Peer Comparison

Key Financials - FY25
Company Name Anglo-French Drugs and Industries Ltd Marksans Pharma Ltd
Listing Status Unlisted Listed
Revenue from Operations 87.79 2,622.84
Total Income 117.99 2,693.22
Finance Cost 1.85 11.66
Depreciation & Amortization 3.27 83.38
Total Expenses 110.13 2,189.25
EBITDA 12.98 599.01
PAT 7.22 382.61
No. of Shares Outstanding 0.12 45.32
EPS (in ₹) 58.54 8.40
Share Capital 1.23 45.31
Total Net Worth 124.80 2,489.38
Total Assets 192.40 3,239.63
Total Debt 19.01 23.08
Key Metrics:
CMP* 1,540.00 236.06
Market Cap (In Cr.) 189.94 10,698.24
Market Cap/Sales 1.61 3.97
EPS (Earnings Per Share) 58.54 8.40
BVPS (Book Value Per Share) 1,011.85 54.93
P/E 26.31 28.10
P/BV 1.52 4.30
EBITDA Margin 14.79% 22.84%
ROE 5.79% 15.37%
ROA 3.75% 11.81%
*Market Price in ₹ as on 05 Jun, 2026

Profit Loss

FY25 FY24 FY23 FY22 FY21
Revenue from operations 87.79 95.20 102.51 164.80 153.78
Y-o-Y Revenue Growth -7.78% -7.13% -37.80% 7.17% 18.13%
Other Income 30.20 4.64 7.59 0.81 1.02
Total Income 117.99 99.84 110.10 165.61 154.80
Total Expenses (Excludes Interest and Depreciation) 105.01 107.13 143.88 156.63 137.42
Operating Profit (After deducting Depreciation) -20.49 -15.08 -44.71 5.27 13.90
OPM % -23.34 -15.84 -43.62 3.20 9.04
EBITDA 12.98 -7.29 -33.78 8.98 17.38
Depreciation 3.27 3.15 3.34 2.90 2.46
EBIT 9.71 -10.44 -37.12 6.08 14.92
Interest 1.85 1.85 3.07 4.27 5.29
EBT before Exceptional Items 7.86 -12.29 -40.19 1.81 9.63
Prior period/Exceptional /Extra Ordinary Items 0.00 0.00 291.27 0.00 0.00
Profit before tax/EBT 7.86 -12.29 251.08 1.81 9.63
Tax 0.64 0.05 60.14 0.36 2.12
Net Profit 7.22 -12.34 190.94 1.45 7.51
Profit (loss) of minority interest 0.00 0.00 0.00 0.00 0.00
Total profit (loss) for period 7.22 -12.34 190.94 1.45 7.51
EPS in Rs 58.54 -100.05 1,478.44 11.23 58.22
EPS Change % -158.51% -106.77% 13,065.09% -80.71% 117.89%
EBITDA Change % -278.05% -78.42% -476.17% -48.33% 24.77%
Profit growth -158.51% -106.46% 13,068.28% -80.69% 141.48%
ROCE 7.14% -5.68% -15.81% 12.60% 40.23%
ROE 5.79% -7.22% 91.43% 7.86% 46.73%
Debt / Equity Ratio 0.15 0.05 0.12 1.88 2.47
Sales growth 3Years -18.94% -14.77%
Sales growth 5Years -7.58%
Dividend per share 1.50 1.50 20.00 1.50

Balance Sheet

FY25 FY24 FY23 FY22 FY21
Share Capital 1.13 1.23 1.29 1.29 1.29
Reserves 123.67 169.67 207.55 17.15 14.78
Total shareholders' funds 124.80 170.90 208.84 18.44 16.07
Borrowings 19.01 8.82 26.06 34.68 39.71
Other Liabilities 15.58 15.10 16.82 19.68 16.05
Total Liabilities 67.60 48.70 64.01 77.20 78.70
Fixed Assets 26.28 17.57 17.94 18.73 13.58
Capital WIP 0.00 0.00 0.00 0.00 0.00
Investments 0.48 125.20 166.99 0.20 0.08
Other Assets 115.44 20.40 10.41 8.28 6.93
Total Assets 192.40 219.60 272.85 95.65 94.77
Cash Equivalents 1.17 2.49 9.14 1.85 1.22
Total Current liability 56.35 35.67 38.07 47.40 57.68
Total Assets -Total Current liabilty 136.05 183.93 234.78 48.25 37.09

Cash Flow

FY25 FY24 FY23 FY22 FY21
Net Cash from / (used in) Operating Activity -16.05 -0.04 184.69 11.71 4.51
Net Cash from / (used in) Investing Activity 44.71 41.36 -170.40 -9.05 -0.79
Net Cash from / (used in) Financing Activity -46.00 -44.06 -11.70 -2.87 -3.31
Net Inc/Dec In Cash And Cash Equivalents 0.13 -2.74 2.59 -0.21 0.41

Share Holding Pattern

No. of Shares in Crs. % Holding
Promoters 0.08 65.24%
Non Promoters 0.04 34.76%

News

India’s First Private Market Benchmark. Providing institutional clarity to the unlisted securities market.

  • +91 98925 31672
  • info@chryseum.in
  • For latest updates
  • © 2026 Chryseum Advisors LLP. All rights reserved. LLPIN – AAD-0626